Akèy › Kasinom Selil Skwamoz Ezofajyen
Etid klinik pou Kasinom Selil Skwamoz Ezofajyen ap rekrite nan Etazini
34 etid pou Kasinom Selil Skwamoz Ezofajyen ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Arlington, VA14 etid
- Nashville, TN12 etid
- Houston, TX12 etid
- Los Angeles, CA11 etid
- Baldwin Park, CA8 etid
- West Valley City, UT7 etid
- San Antonio, TX7 etid
- New York City, NY7 etid
- Santa Monica, CA6 etid
- Queens, NY6 etid
- Dallas, TX5 etid
- Orlando, FL5 etid
- Boston, MA5 etid
- Detroit, MI5 etid
- Fort Worth, TX5 etid
- Austin, TX4 etid
- St. Louis, MO4 etid
- Irvine, CA4 etid
- Atlanta, GA4 etid
- Portland, OR4 etid
- Grand Rapids, MI4 etid
- Cleveland, OH4 etid
- Pittsburgh, PA4 etid
- Chicago, IL3 etid
- Coral Springs, FL3 etid
- Rochester, MN3 etid
- Omaha, NE3 etid
- San Francisco, CA3 etid
- Las Vegas, NV3 etid
- Fullerton, CA3 etid
- Orange, CA3 etid
- Irving, TX3 etid
- New Haven, CT3 etid
- Bridgeport, CT3 etid
- Seattle, WA3 etid
- Durham, NC3 etid
- Philadelphia, PA3 etid
Pa eta
- Arizona6 etid
- Connecticut4 etid
- Florid11 etid
- Georgia4 etid
- Illinois5 etid
- Kalifòni24 etid
- Massachusetts5 etid
- Michigan10 etid
- Minnesota5 etid
- Missouri5 etid
- Nebraska3 etid
- Nevada3 etid
- New Jersey5 etid
- New York14 etid
- North Carolina4 etid
- Ohio8 etid
- Oregon4 etid
- Pennsylvania8 etid
- Tennessee12 etid
- Texas19 etid
- Utah7 etid
- Virginia14 etid
- Washington6 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06780111A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07405151A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT05319730Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06265285177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07189871A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07090499A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07085091A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07277413A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07229313Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07730021A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07109726A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07217171Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06535607A Study of IDP-001 in Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07602842A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT07554521Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT06084481Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT04221893A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT06242470A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT06644781A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT05208762A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT06657144A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT07224750Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT07266363A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.